Summary.-Serum testosterone (T) and dihydrotestosterone (DHT) were measured by a sensitive and reliable radioimmunoassay in 42 normal subjects and 33 agematched patients with carcinoma of the prostate. The mean +s.e. for serum testosterone in normal subjects was 16-74h076nM and the corresponding value for patients with carcinoma was 20-94±1-48nM. Statistical analysis of the results showed a significant increase in T level in patients with carcinoma of the prostate (P<001). In contrast, there was no difference in DHT concentration between the two groups, values being 2-43±0-09 and 206±009nM for normal subjects and patients respectively.
respectively. The difference was highly significant (P<0001). The wide range of variation for T in patients with carcinoma would suggest that although mean T is higher in these patients, this measurement alone is of little practical value, whereas T/DHT ratio is a more reliable parameter in evaluating the androgen changes in these patients. The significance of these findings in relation to the aetiology of the disease is discussed.
PROSTATIC NEOPLASIA and hyperplasia are both diseases of advancing age, and present at a time of life when testicular function is in decline. In normal men the association between ageing and declining plasma androgen levels is now becoming clearer (Editorial, Brit. med. J., 1975; Lewis et at., 1976) . However, the growth and continued function of both benign hyperplasia and carcinoma are dependent on the continued availability of androgens (Huggins & Hodges, 1941; Ghanadian et al., 1975a) . Hence the development of these conditions at this particular time appears to be something of a paradox.
Data on androgen levels in carcinoma of the prostate are sparse and at times conflicting; rather more information has recently become available from studies in patients with benign hyperplasia. High tissue levels of dihydrotestosterone (DHT) have been reported in benign hyperplasia (Siiteri & Wilson, 1970) and circulating plasma levels of this steroid have been found to be higher in patients with BPH than in normal subjects (Horton et al., 1975; Vermeulen & Desy, 1976; Ghanadian et al., 1977) . However, this latter finding has not been detected by some investigators (Harper et al., 1976) . Studies on androgen levels in prostatic tissue indicate that the concentration of testosterone (T) is significantly higher in carcinoma than in BPH (Habib et al., 1976) . The present study was designed to investigate changes in plasma T and DHT in patients with carcinoma of the prostate and agematched controls, to relate these findings to the clinical picture and to evaluate the possible implications to the aetiology of this disease.
Correspondence to Dr R. Ghanadian. Thirty-three patients with histologically proven carcinoma of the prostate, aged 56-85 years, and 42 normal men aged 50-81 years were used in this study. The mean ages ±s.e. for these two groups were 6941 and 61+1 respectively. The patients had received no treatment for their disease. The normal subjects were all in good health and free from urological and endocrinological symptoms. They were chosen from a screening unit where they had attended for a routine medical examination.
Venous blood was drawn between 10.00 and 12.00 hours. Serum was separated within 30 min of collection and stored at -20°C before assay.
Testosterone and 5 cy-dihydrotestosterone were measured by a sensitive and reliable radioimmunoassay technique developed in our laboratory (Ghanadian et al., 1975b) . Antibody was generated in New Zealand white rabbit against testosterone 3-oxime coupled to bovine serum albumin, and the specificity of this antiserum was extensively studied. The within-assay variation on human pool serum gave a coefficient of variation of 11-6 % for T and 6.5% for DHT. The between-assay variation was found to be 9.2% and 6 5% for T and DHT respectively. The sensitivity of this technique for T was 17-4pM and for dihydrotestosterone 344pM. The two steroids were separated by thin-layer chromatography and subsequently assayed. RESULTS Serum T and DHT were measured in 42 normal subjects and 33 patients with carcinoma of the prostate. The results are (Pirk & Doerr, 1973 with an age range of 50 to 81 years and esults clearly demonstrate that the found no significant difference. Two other T in patients with carcinoma of the groups (Harper et al., 1976 and Bartsch is higher than in age-matched et al., 1977a) also reported no significant of normal subjects, with a wide change in calculating T in prostatic carf values for each group. A promi-cinoma, but both of these investigative crease was also seen in the ratio groups estimated T without any purificain patients with prostatic cancer. tion to exclude interference from DHT. rameter was found to be a more
We have found no significant change in index in assessing androgen serum DHT in patients with carcinoma of in these patients than T levels the prostate compared to normal subjects, in contrast to our T data. The level of .e present study unconjugated T DHT in our patients was 2-0610.20nM, 'T (i.e. the free and protein-bound which is of the same order of magnitude s) were measured. Most of the reported by others (Habib et al., 1976: ing T and DHT are bound to pro-2-4±0-5nM). Bartsch et al. (1977a) (Bartsch et al., 1977b) .
The importance of the measurement of DHT lies in its relationship to T, as the ratio of these two steroids could provide a more reliable criterion for the assessment of circulating androgens in this disease. The high level of T in the circulating blood and prostatic tissues of patients with carcinoma of the prostate suggests that, unlike in BPH, T may play an important role in the development of prostatic carcinoma. The increased T in these patients may be derived either from the overproduction of this steroid by the testis or by a more active conversion of androstenedione to T by the adrenal.
Although the mean testosterone in patients with carcinoma of the prostate is higher than in normal controls, the scattered individual values for this steroid indicate little practical application in the diagnosis of the prostatic cancer. However, the combined measurement of T and DHT provides a more significant criterion for assessment.
